To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Representative for Oregon's 5th congressional district. Democrat.
Last Updated: Apr 26, 2021
Length: 3 pages
117th Congress (2021–2023)
This bill was introduced on April 26, 2021, in a previous session of Congress, but it did not receive a vote.
Although this bill was not enacted, its provisions could have become law by being included in another bill. It is common for legislative text to be introduced concurrently in multiple bills (called companion bills), re-introduced in subsequent sessions of Congress in new bills, or added to larger bills (sometimes called omnibus bills).
What legislators are saying
“Schrader Issues Statement Following FDA's Budget Request Includes His Proposal To Close Loophole in Generic Drug Approval Process”
— Rep. Kurt Schrader [D-OR5, 2009-2022] (Sponsor) on Mar 29, 2022
Apr 26, 2021
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
May 4, 2021
Considered by Health
A committee held a hearing or business meeting about the bill.
H.R. 2853 (117th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number H.R. 2853. This is the one from the 117th Congress.
This bill was introduced in the 117th Congress, which met from Jan 3, 2021 to Jan 3, 2023. Legislation not passed by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2023). H.R. 2853 — 117th Congress: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021. Retrieved from https://www.govtrack.us/congress/bills/117/hr2853
“H.R. 2853 — 117th Congress: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021.” www.GovTrack.us. 2021. March 21, 2023 <https://www.govtrack.us/congress/bills/117/hr2853>
Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021, H.R. 2853, 117th Cong..
|title=H.R. 2853 (117th)
|accessdate=March 21, 2023
|author=117th Congress (2021)
|date=April 26, 2021
|quote=Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021
- show another citation format:
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.